Oncotelic Launches PDAO SEC Chatbot
AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We” or “Our”), , today announced the beta launch of a proprietary SEC chatbot, utilizing our DAO token (PDAO) and Artificial Intelligence (AI). This chatbot allows users to receive conversational responses about the Company’s SEC filings filed as of April 12, 2023.
Related news for (OTLC)
- Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence
- ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
- ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
- ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING
- Linkage of Cancer and Lupus in Gliomas Patients